• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Cabozantinib may be a viable first-line treatment in metastatic renal cell collecting duct carcinoma

byJohan PushaniandSze Wah Samuel Chan
April 25, 2022
in Nephrology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Objective response rate was 35%, with 1 patient showing a complete response and 7 showing a partial response.

2. Most common adverse events included fatigue, anorexia, hand-foot syndrome, hypothyroidism, and mucositis.

Evidence Rating Level: 2 (Good)

Study Rundown: Cabozantinib’s benefit in non-clear cell renal cell carcinoma (ncRCC) has been previously documented. This study explored the use of cabozantinib (an inhibitor of multiple tyrosine kinase receptors) on patients with metastatic collecting duct carcinoma (mCDC), a rare type of ncRCC with a poor prognosis. Patients were only assigned to a treatment group, and were given cabozantinib until disease progression, onset of unacceptable toxic effects or withdrawal. The primary end point was objective response rate (ORR), defined by patients having a complete or partial response, and was found to be 35%. Median time to data censor was 11 months, median progression-free survival (PFS) was 4 months, and median overall-survival (OS) was 7 months. When indirectly compared to other first-line treatments for mCDC, cabozantinib yielded a higher ORR, and similar median PFS and median OS though there is caution in cross-trial comparisons. Adverse events of grades 1 and 2 occurred in all patients, notably including fatigue, anorexia, hand-foot syndrome, hypothyroidism, and mucositis. Adverse events of grade 3 were higher with cabozantinb than the other first-line therapies. Limitations to this study include the small sample size, predominantly male participants, and the fact that this study was only performed in Italy. It is also limited by its indirect comparison of cabozantinib and other first-line therapies. The strength of this study is that it provides a treatment option to mCDC, which normally has a poor prognosis. Overall, this study demonstrated that cabozantinib as a first-line therapy for patients with mCDC is hypothesis generating and warrants further studies.

Click to read the study in JAMA Oncology

Relevant Reading: Characteristics and treatment challenges of non-clear cell renal cell carcinoma

In-Depth [prospective cohort]: This phase II, single-arm clinical trial in Italy included 23 patients with mCDC. The ORR was 35% (95% confidence interval [CI], 16% to 57%), the median time to censoring was 11 months (95% CI, 0 to 22 months), the median PFS was 4 months (95% CI, 3 to 13 months), and median OS was 7 months (95% CI, 3 to 31 months). When indirectly compared to standard therapy regimen for mCDC (carboplatin plus gemcitabine), cabozantinib had a 9% increase in ORR and similar PFS and OS. Adverse events of grades 1 and 2 occurred in all patients, with the most common being fatigue (60%), anorexia (39%), hand-foot syndrome (30%), hypothyroidism (30%), and mucositis (30%). Adverse events of grade 3 occurred more with cabozantinib when indirectly comparing it to standard mCDC therapy +/- sorafenib. Overall, cabozantinib led to an ORR of 35% and may be a promising first-line treatment but will need more studies to further investigate.

RELATED REPORTS

Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma

Cabozantinib is associated with an intracranial response in the treatment of brain metastases from renal cell carcinoma

#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cabozantinibcollecting duct carcinomapapillary renal cell carcinoma
Previous Post

Telemedicine bridge clinics may be helpful for opioid use disorder treatment

Next Post

Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation

RelatedReports

Pediatric renal and thyroid cancer rates increase
Oncology

Telaglenastat addition to cabozantinib did not demonstrate benefit in pre-treated advanced renal cell carcinoma

September 12, 2022
Quick Take: Association of a Schizophrenia-Risk Nonsynonymous Variant With Putamen Volume in Adolescents A Voxelwise and Genome-Wide Association Study
Neurology

Cabozantinib is associated with an intracranial response in the treatment of brain metastases from renal cell carcinoma

October 25, 2021
#VisualAbstract: Tocilizumab reduced COVID-19 disease related adverse health outcomes
StudyGraphics

#VisualAbstract: Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

March 11, 2021
Galangin may sensitize apoptosis-resistant renal carcinoma cells [PreClinical]
Nephrology

Nivolumab and cabozantinib superior to sunitinib for advanced renal-cell carcinoma

March 10, 2021
Next Post
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ

Comparison of mastectomy and breast reconstruction versus conservative surgery with radiation

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Spectrophotometric assays for methadone may be effective for diversion control

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options